Drug Profile
BR 6819
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Bayer
- Class Cardiovascular therapies
- Mechanism of Action Vasopressin 1a receptor antagonists; Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in Germany (PO)
- 11 Nov 2017 Phase-I clinical trials in Heart failure (In volunteers) in Germany (PO)
- 11 Nov 2017 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in healthy male volunteers presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)